We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

By LabMedica International staff writers
Posted on 17 May 2022

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. More...

Hearing loss is one of the top contributors to years lived with disability and is a risk factor for developing dementia. Hearing loss is a major medical problem worldwide with an estimated 2.4 billion individuals expected to have some form of hearing loss by the year 2050.

Molecular evidence on the cellular origins of hearing loss in humans is growing. In this regard, investigators at King's College London (United Kingdom) and colleagues at Karolinska Institute (Stockholm, Sweden) and Erasmus University (Rotterdam, Netherlands) performed a genome-wide association meta-analysis of clinically diagnosed and self-reported hearing impairment on 723,266 individuals. The study comprised 147,997 affected individuals and 575,269 control subjects including 60,941 affected individuals that were not included in a previously published GWAS meta-analysis.

Results of the meta-analysis revealed 48 genes linked to hearing loss, including 10 novel variants newly linked to hearing.

Contributing author Dr. Frances Williams, professor of genomic epidemiology at King's College London, said, "Our findings identify 10 genes newly linked with hearing loss. This study points to genes we could target for screening purposes, drug development. and even gene therapy in the future. This study provides a solid foundation for ultimately improving therapies against hearing loss."

The study was published in the May 16, 2022, online edition of the American Journal of Human Genetics.

Related Links:
King's College London 
Karolinska Institute 
Erasmus University 

 


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
8-Channel Pipette
SAPPHIRE 20–300 µL
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.